|
|
| Home | Stock Market Blogs | Financial Tools | Sign Up Free | |
| KERYX BIOPHARMACEU | |
||||||||||||||||||||||||||||||||||||||||||||||||||||
| KERYX BIOPHARMACEU | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KERX | Last: $4.21 ($+0.10) | Volume: 2,045,512 | Last Trade: 8/5/2010 5:20:01 PM | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Today
Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
| KERYX BIOPHARMACEU Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Keryx Biopharmaceuticals is a biopharmaceutical company focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Co.'s lead compound under development is Sulonex? (sulodexide), a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Additionally, Co. is developing Zerenex? , an oral, inorganic, iron-based compound, as well as clinical-stage oncology compounds, including KRX-0401 , a novel, first-in-class, oral anti-cancer agent. Co. also has an active in-licensing and acquisition program. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| KERYX BIOPHARMACEU News & Press Releases | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2010 Financial Results NEW YORK , May 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. ( KERX ), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products fo... [more] Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2009 Financial Results NEW YORK , March 24 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. ( KERX ), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products... [more] Keryx Biopharmaceuticals, Inc. To Hold Conference Call on Fourth Quarter and Year-End 2009 Financial NEW YORK , March 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. ( KERX ) will hold a conference call on Thursday, March 25, 2010 at 8:30 a.m. EDT to discuss the fourth quarter and year... [more] Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study f LOS ANGELES, CA -- (Marketwire) -- 02/05/10 -- BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that Keryx Biop... [more] Beacon Equity issues Trading Overview for Keryx Biopharmaceuticals ( EMAILWIRE.COM , October 15, 2009 ) DALLAS, Texas - BeaconEquity.com announces an investment report featuring Keryx Biopharmaceuticals (Nasdaq:KERX). The investment report on Keryx Biopharmaceuticals (Nasdaq: KERX) should be of particul... [more] Keryx Biopharmaceuticals, Inc. to Raise $20 Million in Registered Direct Offering NEW YORK, Sept. 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (the "Company") ( KERX ), has entered into definitive agreements to sell 8 million shares of its common stock at a price per sh... [more] Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results Keryx to Host Investor Conference Call on Friday, March 13, 2009 at 8:30am EDT NEW YORK , March 12 /PRNewswire-FirstCall/ -- Keryx Biopharmaceutic... [more] Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial NEW YORK , March 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. ( KERX ) will hold a conference call on Friday, March 13, 2009 at 8:30 a.m. EDT to... [more] Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results NEW YORK , Nov. 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. ( KERX ), a biopharmaceutical company focused on the acquisition, development and commercialization of med... [more] Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tu NEW YORK , Nov. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. ( KERX ) will hold a conference call on Tuesday, November 11, 2008 at 8:30 a.m. EST t... [more] Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period NEW YORK , Oct. 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. ( KERX ) announced today that it has received notice from The Nasdaq Stock Market ("Nasdaq") stating that Nasd... [more] Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results NEW YORK , Aug. 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. ( KERX ), a biopharmaceutical company focused on the acquisition, development and commercialization of medi... [more] Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results NEW YORK, May 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. KERX , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatme... [more] Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Mo NEW YORK, May 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. KERX will hold a conference call on Monday, May 12, 2008 at 8:30 a.m. EDT to discuss the first quarter 2008 financial results. Michael S. Weiss, Chairman and Chief E... [more] Keryx Biopharmaceuticals Receives Nasdaq Notification NEW YORK, April 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. KERX announced today that it has received notice from The NASDAQ Stock Market ("Nasdaq") stating that the Company is not in compliance with the $1.00 minimum bid... [more] |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign Up | Copyright © 2013 SmallCapWatch, LLC. |
| Never invest based soley on information from this website or our e-mail and IM alerts | |
